

1 **Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by**
2 **virus neutralisation and commercial assays**

3 Antonin Bal^{1,2*}, Mary-Anne Trabaud^{1*}, Jean-Baptiste Fassier^{3,4}, Muriel Rabilloud^{5,6}, Kahina Saker¹,
4 Carole Langlois-Jacques^{5,6}, Nicolas Guibert^{3,4}, Constance d'Aubarede^{3,4}, Adèle Paul^{3,4}, Dulce
5 Alfaiate⁷, Amélie Massardier-Pilonchery^{3,4}, Virginie Pitiot⁴, Florence Morfin-Sherpa^{1,2}, Bruno
6 Lina^{1,2}, Bruno Pozzetto^{8,9*}, Sophie Trouillet-Assant^{1,2*} on behalf the COVID SER STUDY GROUP
7

8 ¹Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de
9 Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France

10 ² CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Inserm, U1111,
11 Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France

12 ³ Université Claude Bernard Lyon1, Ifsttar, UMRESTTE, UMR T_9405, Lyon, France

13 ⁴ Service de Médecine et Santé au Travail, Hospices Civils de Lyon, Lyon, France.

14 ⁵ Université de Lyon, F-69000, Lyon, France; Université Lyon 1, Villeurbanne, France; Hospices
15 Civils de Lyon, Pôle Santé Publique, Service de Biostatistique et Bioinformatique, Lyon, France

16 ⁶ CNRS, UMR 5558, Université de Lyon, Laboratoire de Biométrie et Biologie Evolutive, Equipe
17 Biostatistique-Santé, Villeurbanne, France.

18 ⁷ Service des Maladies Infectieuses et Tropicales, Hôpital de la Croix Rousse, Hospices Civils de
19 Lyon, Lyon, France

20 ⁸ GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), Université Jean
21 Monnet, Université de Lyon, Saint-Etienne, France

22 ⁹ Laboratoire des agents infectieux et hygiène, Hospital Universitaire de Saint-Etienne, Saint-
23 Etienne, France

24

25 * Authors contributed equally to the manuscript

26 **Corresponding author:** Dr Sophie Trouillet-Assant, Ph.D

27 Hospices Civils de Lyon, France

28 Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111,
29 Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France

30 Phone: + 33 (0)472678780 Email: sophie.assant@chu-lyon.fr

31

32 **Keywords:** COVID-19; SARS-CoV-2; Serological assays; Virus neutralisation assay; Healthcare

33 workers

34 **Abstract**

35

36 We conducted a prospective study in healthcare workers (n=296) of the University Hospital of
37 Lyon, France. Serum samples (n=296) collected six months after disease onset were tested using
38 three commercial assays: the Wantai Ab assay detecting total antibodies against the receptor
39 binding domain (RBD) of the S protein, the bioMerieux Vidas assay detecting IgG to the RBD and
40 the Abbott Architect assay detecting IgG to the N protein. The neutralising antibody (NAb) titre
41 was also determined for all samples with a virus neutralisation assay (VNA) using live virus. The
42 positivity rate was 100% with the Wantai assay, 84.8% with the bioMerieux assay and 55.4% with
43 the Abbott assay. Only 51% of HCWs were positive for the presence of NAb. Less than 10 % of
44 HCWs had a NAb titre greater than 80. At a neutralising titre of 80, the area under the curves [IC
45 95%] was 0.71 [0.62-0.81], 0.75 [0.65-0.85] and 0.95 [0.92-0.97] for Wantai, Abbott and Vidas
46 respectively. The data presented herein suggest that commercial assays detecting antibodies against
47 the N protein must not be used in long-term seroprevalence surveys while the Wantai assay could
48 be useful for this purpose. VNA should remain the gold standard to assess the protective antibody
49 response, but some commercial assays could be used as first-line screening of long-term presence of
50 NAb.

51 To the Editor,

52 Since the SARS-CoV-2 emergence in December 2019, one of the major concerns is the duration of
53 immune protection after a first episode. This question is of paramount importance for healthcare
54 workers (HCWs) who are a highly exposed population and among the first targets of vaccination
55 programmes. To date, the persistence of SARS-CoV-2 antibodies in HCWs six months after disease
56 onset (ADO) has not been studied with both a virus neutralisation test and commercial assays.

57 HCWs who experienced COVID-19 during the early phase of the pandemic were included in a
58 prospective study conducted at the University Hospital of Lyon, France [1]. Serum samples
59 collected six months ADO were tested using three commercial assays: the Wantai Ab assay that
60 detects total antibodies against the receptor binding domain (RBD) of the S protein, the bioMérieux
61 Vidas assay that detects IgG to the RBD, and the Abbott Architect assay that detects IgG to the N
62 protein. The neutralising antibody (NAb) titre was determined by a virus neutralisation assay
63 (VNA) using live virus as previously described [2].

64 A total of 296 HCWs were included; the median [interquartile range, IQR] age was 41 [32-51]
65 years and 17.2% (51/296) were male. The median duration between symptom onset and inclusion
66 was 186 [180-196] days. Of note, 8/296 HCWs (2.7%) were asymptomatic and the onset of disease
67 was established on the basis of the median date of the RT-PCR positive result of the ward cluster.
68 All participants were tested positive for SARS-CoV-2 serology at least two weeks after disease
69 onset. The SARS-CoV-2 infection was also documented by RT-PCR test in 170 patients.

70 The positivity rate at six months ADO was 100% with the Wantai assay, 84.8% with the Vidas
71 assay, and 55.4% with the Architect assay. Only 51% of HCWs were positive for the presence of
72 NAb. Positive NAb titres ranged from 20 to 240. Only 27/296 (9.1%) had a NAb \geq 80 (Figure 1A).
73 No difference in positivity rates with any assay was observed between patients with a SARS-CoV-2
74 infection documented by RT-PCR and the rest of the cohort.

75 Of the 296 HCWs, 6 (2.0%) developed a clinical form requiring hospitalisation; all were positive
76 with the three serological assays and for the presence of NAb with a median titre of 40 (range: 30-

77 160). By contrast, in asymptomatic HCWs, 8/8, 5/8, and 4/8 were positive with Wantai, Vidas, and
78 Architect assays, respectively, and only 3/8 exhibited NAb with low titres (range: 30-60).
79 The area under the ROC curve (AUC) was estimated for assessing the performance of serological
80 assays for two NAb titres ($\text{PRNT}_{50} \geq 20$ or $\text{PRNT}_{50} \geq 80$; (Figure 1C, E, G). The highest AUCs
81 were found with the Vidas assay: 0.85 (95% CI [0.81-0.89]) and 0.95 [0.92-0.97], respectively. The
82 Wantai and Abbott assays had AUCs of, respectively, 0.73 [0.68-0.79] and 0.70 [0.64-0.76] for
83 $\text{PRNT}_{50} \geq 20$, and 0.71 [0.62-0.81], 0.75 [0.65-0.85] for $\text{PRNT}_{50} \geq 80$. These results suggest that an
84 optimised ratio with some commercial serological assay could be found to maximize the positive
85 predictive value enabling to select individuals with a NAb titres ≥ 80 . For instance, with the Vidas
86 assay, the median [IQR] ratio for samples with $\text{PRNT}_{50} \geq 80$ was 15.4 [9.7-22.7] vs 5.9 [3.3-9.2] for
87 samples with a titre between 20 and 80 and 1.8 [0.8-3.8] for samples without NAb (Figure 1F).
88 Among the 27 samples with NAb titre ≥ 80 , all had a Vidas ratio above 8 compared to 31.5% and
89 3.5% of the samples with a titre between 20 and 80 or without NAb, respectively.
90 The findings of the present study indicate that, six months after infection, NAb were no longer
91 detected in about half of HCWs who presented mainly mild COVID-19. Overall, the detection of
92 SARS-CoV-2 Abs with commercial tests was higher despite important heterogeneity between the
93 assays evaluated herein. In a previous study [3], about 40% of asymptomatic subjects became
94 negative for IgG to the N protein within 3 to 6 months, which is consistent with that presented
95 herein for the Architect assay. This suggests that assays detecting only antibodies against the N
96 protein must not be used in long-term seroprevalence surveys. By contrast, the Wantai assay could
97 be very useful for epidemiological purposes as 100% of the HCWs were still positive at 6 months
98 ADO. Although VNA should remain the gold standard to assess the protective antibody response,
99 the data presented herein suggest that some commercial assays could be useful for first-line
100 screening of long-term presence of NAb as previously reported within 4 months ADO [2,4].

101 Despite these observations on the decrease of NAbS in patients with mild COVID-19, it is important
102 to note that they do not preclude the protective role of an anamnestic antibody response in
103 previously exposed subjects, nor that of the long-term cellular immunity [5].

104 **References**

- 105 [1] Trouillet-Assant S, Albert Vega C, Bal A, Nazare JA, Fascia P, Paul A, et al. Assessment of
106 serological techniques for screening patients for COVID-19 (COVID-SER): a prospective,
107 multicentric study. *BMJ Open* 2020;10:e041268. [https://doi.org/10.1136/bmjopen-2020-](https://doi.org/10.1136/bmjopen-2020-041268)
108 [041268](https://doi.org/10.1136/bmjopen-2020-041268).
- 109 [2] Bal A, Pozzetto B, Traubad M-A, Escuret V, Rabilloud M, Langlois-Jacques C, et al.
110 Evaluation of high-throughput SARS-CoV-2 serological assays in a longitudinal cohort of mild
111 COVID-19 patients: sensitivity, specificity and association with virus neutralization test.
112 *MedRxiv* 2020:2020.09.30.20194290. <https://doi.org/10.1101/2020.09.30.20194290>.
- 113 [3] Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA, et al. Orthogonal
114 SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and
115 Reveal Durable Humoral Immunity. *Immunity* 2020;53:925-933.e4.
116 <https://doi.org/10.1016/j.immuni.2020.10.004>.
- 117 [4] Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, et al. Longitudinal
118 analysis of serology and neutralizing antibody levels in COVID19 convalescents. *J Infect Dis*
119 n.d. <https://doi.org/10.1093/infdis/jiaa659>.
- 120 [5] Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD, et al. Functional
121 SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. *Cell* 2020;0.
122 <https://doi.org/10.1016/j.cell.2020.11.029>.
- 123

124 **Figure legend:**

125 **A.** Distribution of neutralisation antibody titres in convalescent subjects (n=296) 6 months after
126 SARS-CoV-2 infection. **B-D-F.** Violin plots describing ODR according to neutralising antibody
127 titres. Dotted lines described positive threshold recommended by each manufacturer. Comparisons
128 was performed using the Kruskal Wallis test followed by Dunn's test. ***p<0.001, *p<0.05 **C-E-G.**
129 ROC curves were built to estimate the performance of Wantai (C), bioMérieux (E) and Abbott (G)
130 assays for detecting the presence of neutralising antibodies (PRNT₅₀ ≥ 20-continuous line) and high
131 neutralising antibody titre (PRNT₅₀ ≥ 80-dotted line). ODR-Optical Density Ratio, PRNT-Plaque
132 Reduction Neutralisation Titres.

133 **Ethics**

134 Written informed consent was obtained from all participants; ethics approval was obtained from the
135 national review board for biomedical research in April 2020 (Comité de Protection des Personnes
136 Sud Méditerranée I, Marseille, France; ID RCB 2020-A00932-37), and the study was registered on
137 ClinicalTrials.gov (NCT04341142).

138 **COVID-SER study group**

139 Adnot Jérôme, Alfaiate Dulce, Bal Antonin, Bergeret Alain, Boibieux André, Bonnet Florent,
140 Bourgeois Gaëlle, Brunel-Dalmas Florence, Caire Eurydice, Charbotel Barbara, Chiarello Pierre,
141 Cotte Laurent, d'Aubarede Constance, Durupt François, Escuret Vanessa, Fascia Pascal, Fassier
142 Jean-Baptiste, Fontaine Juliette, Gaillot-Durand Lucie, Gaymard Alexandre, Gillet Myriam,
143 Godinot Matthieu, Gueyffier François, Guibert Nicolas, Josset Laurence, Lahousse Matthieu, Lina
144 Bruno, Lozano Hélène, Makhloufi Djamilia, Massardier-Pilonchéry Amélie, Milon Marie-Paule,
145 Moll Frédéric, Morfin Florence, Narbey David, Nazare Julie-Anne, Oria Fatima, Paul Adèle, Perry
146 Marielle, Pitiot Virginie, Prudent Mélanie, Rabilloud Muriel, Samperiz Audrey, Schlienger Isabelle,
147 Simon Chantal, Traubaud Mary-Anne, Trouillet-Assant Sophie

148 **Acknowledgements**

149 We thank all the personnel of the occupational health and medicine department of Hospices Civils
150 de Lyon who contributed to the samples collection. Human biological samples and associated data
151 were obtained from NeuroBioTec (CRB HCL, Lyon France, Biobank BB-0033-00046). We thank
152 Karima Brahima and all members of the clinical research and innovation department for their
153 reactivity (DRCI, Hospices Civils de Lyon). We thank Philip Robinson (DRCI, Hospices Civils de
154 Lyon) for his help in manuscript preparation.

155 **Conflict interests statement**

156
157 Antonin Bal has received grant from bioMérieux and has served as consultant for bioMérieux
158 for work and research not related to this manuscript. Sophie Trouillet-Assant has received
159 research grant from bioMérieux concerning previous works not related to this manuscript.
160 The other authors have no relevant affiliations or financial involvement with any organisation
161 or entity with a financial interest in or financial conflict with the subject matter or materials
162 discussed in the manuscript.

